You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Severe exacerbation of Crohns disease during sunitinib treatment

Boers-Sonderen, Marye J.a; Mulder, Sasja F.a; Nagtegaal, Iris D.b; Jacobs, Joannes F.M.a,c,d; Wanten, Geert J.e; Hoentjen, Franke; van Herpen, Carla M.a

European Journal of Gastroenterology & Hepatology:
doi: 10.1097/MEG.0b013e328365ac54
Case Reports
Abstract

Sunitinib is a multiple tyrosine kinase inhibitor of the vascular endothelial growth factor and platelet-derived growth factor pathway and inhibits angiogenesis, cell proliferation, and tumor cell invasion, and stimulates apoptosis. Treatment with sunitinib in first-line metastatic renal cell carcinoma improves progression-free survival and overall survival compared with interferon-α. Crohn’s disease is characterized by chronic immune-mediated intestinal inflammation. Although the exact pathogenesis of Crohn’s disease remains unknown, the involvement of angiogenesis is acknowledged. It is unknown whether sunitinib interferes with the natural course of Crohn’s disease. We describe a patient with metastatic renal cell carcinoma and a history of Crohn’s disease who was treated with sunitinib and developed a severe exacerbation of Crohn’s disease. After rechallenge with sunitinib, a second exacerbation occurred. We therefore conclude that angiogenesis inhibitors should be administered with care in patients with a history of Crohn’s disease.

Author Information

Departments of aMedical Oncology

bPathology

cTumor Immunology

dLaboratory Medicine

eGastroenterology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Correspondence to Marye J. Boers-Sonderen, MD, Department of Medical Oncology (452), Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands Tel: +31 24 3610353; fax: +31 24 3540788; e-mail: m.boers-sonderen@aig.umcn.nl

Received June 12, 2013

Accepted August 7, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins